Back to Agenda
Enabling Patient Access Worldwide Including Japan or Other Countries to Innovative Drugs Through Global Development Strategy
Session Chair(s)
Eri Sekine
Executive Vice President
CMIC Group, Japan
This forum will present the considerations in global development strategy to approach to broader market including Japan for maximizing worldwide patient access and business opportunity. The panelists are from pharma and biotech.
Learning Objective : Describe how to maximize the value of innovative products for the global market and benefit patients worldwide; Discuss how to apply the learnings to the clinical development strategy to expand target market effectively considering patient access to innovative drugs; Identify how to influence to regulators, industry, and trial sites to improve local environment to reduce hurdles and enhance global simultaneous development.
Speaker(s)
Panelist
Leyna Mulholland, PharmD, PhD, MS
Transent Group, United States
Executive Director, Global Regulatory Affairs
Panelist
Toshiharu Sano, RPh
MSD K.K., Japan
Associate Vice President, Head of Clinical Operation Area
Panelist
Xiaojun (Wendy) Yan, MD, MBA
BeiGene (Beijing) Co., Ltd., China
Senior Vice President, Chief Regulatory Officer
Have an account?